Scientific Program

Saturday 10/06/2023

15:00 Registration

Opening Session

17:30 Opening of the Symposium and Welcome address

Prof. Daniel HARKI

(UNIVERSITY OF MINNESOTA, Minneapolis, MN, United States)

17:45 PL01- Medicinal Chemistry of the Future: Trends, Targets and Technologies

Dr Klaus URBAHNS

(EMD SERONO, Billerican, MA, United States)

18:30 Welcome Reception

Scientific Program

Sunday 11/06/2023

08:00 Registration

Session 1 - Chemical Modulation of RNA

Session chair

Dr Darby SCHMIDT (SONATA THERAPEUTICS, Cambridge, MA, United States)

09:00 IL01 - Modulating the Conformation and Function of Disease-Relevant RNA with Small Molecules

Prof. Amanda HARGROVE (DUKE UNIVERSITY, Durham, NC, United States)

09:30 IL02 - Targeting Non-Coding RNAs Using Synthetic Small Molecules: Original Targets for Innovative Therapies

Dr Maria DUCA (UNIVERSITY OF CÔTE D'AZUR, Nice, France)

10:00 IL03 - Discovery and Development of Selective Splicing Modifiers as Therapeutics

Dr Matthew WOLL (PTC THERAPEUTICS, South Plainfield, NJ, United States)

10:15 IL04 - Small Molecules Targeting RNA - a Safety Perspective

Dr Helen Louise LIGHTFOOT (F. HOFFMANN-LA ROCHE AG, BASEL, Switzerland)

10:30 Coffee break & Exhibition

Session 2 - Advances in Targeted Protein Degradation

Session chair

Prof. Terry MOORE (UNIVERSITY OF ILLINOIS, Chicago, IL, United States)

11:00 IL05 - Ligand Directed Degradation: from Proof-of-Concept Degradation to Clinical Studies

Dr Deborah MORTENSEN (BRISTOL MYERS SQUIBB, San Diego, CA, United States)

11:30 IL06 - Chemical Approaches to Edit Post-Translational Modification In Cells

Prof. Christina WOO (HARVARD UNIVERSITY, Cambridge, MA, United States)

12:00 OC01 - Treatment of Pediatric AML Via Protac-Mediated Degration of CDK9

Ms Alexandria CHAN (UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY, Baltimore, United States)

12:15 OC02 - Targeting Progerin Degradation as a New Therapeutic Approach for Treating Progeria

Prof. Silvia ORTEGA-GUTIERREZ (COMPLUTENSE UNIVERSITY, Madrid, Spain)

12:30 Lunch & Exhibition

Scientific Program

12:45 Company Workshop by Pelago Bioscience: CETSA® Enabled Drug Discovery: An Applied Workshop on Target Identification/Validation and Target Engagement-Driven Lead Generation and Optimization

Dr Fredrik RAHM (PELAGO BIOSCIENCE, Solna, Sweden)
Dr Stina LUNDGREN (PELAGO BIOSCIENCE, Solna, Sweden)

Session 3 - Proximity-inducing Molecules and their Therapeutic Applications

Session chair

Dr Amit CHOUDHARY (THE BROAD INSTITUTE, Cambridge, MA, United States)

14:00 IL07 -Chemoproteomic-Enabled Development of Proximity-Inducing Molecules

Dr Christopher PARKER (THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA, United States)

14:30 IL08 - An Intramolecular Bivalent Degrader Glues an Intrinsic BRD4-DCAF16 Interaction

Prof. Alessio CIULLI (UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

15:00 OC03 - Discovery of MRT-2359, an Orally Bioavailable GSPT1 Molecular Glue Degrader, for MYC-Driven Cancers

Dr Bernhard FASCHING (MONTE ROSA THERAPEUTICS, Basel, Switzerland)

15:15 OC04 - Integrated Platform Approach for Molecular Degrader Discovery in Proxidrugs

Dr Johanna HUCHTING (FRAUNHOFER INSTITUTE FOR TRANSLATIONAL MEDICINE AND PHARMACOLOGY, Hamburg, Germany)

15:30 Coffee break & Exhibition

16:00 PL02 - RIPTACs: A New 'Hold and Kill'-based Therapeutic Modality

Prof. Craig CREWS (YALE UNIVERSITY, New Haven, CT, United States)

16:45 Poster session 1 (odd numbers)

18:00 End of the scientific programme

18:10 City Tour

Scientific Program

Monday 12/06/2023

08:00 ACMEDI-YMCC | EFMC-YSN Programme for Early Career Researchers

Chair

Dr Melissa GRENIER-DAVIES (GLAXOSMITHKLINE, Cambridge, MA, United States)

08:00 Panel Discussion - "Landing a Job in Industry"

Dr Chris DE GRAAF (SOSEI HEPTARES, Cambridge, United Kingdom)
Dr Abdellatif EL MARROUNI (MERCK & CO., West Point, United States)
(SANOFI-AVENTIS DEUTSCHLAND GMBH)
Dr Malin LEMURELL (ASTRAZENECA, Gothenburg, Sweden)
Dr Darby SCHMIDT (SONATA THERAPEUTICS, Cambridge, MA, United States)

Session 4 - Drug Targets in GPCR Signaling

Session chair

Prof. György KESERU (HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

09:00 IL09 - New Hot Targets? Medicinal Chemistry of G Protein-Coupled Receptors Involved in Immunity and

Prof. Christa MÜLLER (UNIVERSITY OF BONN, Bonn, Germany)

09:30 IL10 - Frontier SBDD across the Orthosteric and Allosteric GPCRome

Dr Chris DE GRAAF (SOSEI HEPTARES, Cambridge, United Kingdom)

10:00 OC05 - Best-In-Class Orally Bioavailable CXCR4 Antagonists to Treat Renal Cell Carcinoma

Dr Eric MILLER (EMORY UNIVERSITY SCHOOL OF MEDICINE, Atlanta, United States)

10:15 OC06 - Targeting Sodium Binding Pocket in Mu Opioid Receptor to Design Safer Analgesics

Dr Susruta MAJUMDAR (UHSP & WASHINGTON UNIVERSITY, Saint Louis, United States)

10:30 Coffee break & Exhibition

Session 5 - Organic Synthesis Impacting Medicinal Chemistry & Chemical Biology

Session chair

Prof. Rui MOREIRA (UNIVERSITY OF LISBON, Lisbon, Portugal)

11:00 IL11 - Photocatalysis in the Pharmaceutical Industry: Synthesis under a New Light

Dr Giulia BERGONZINI (ASTRAZENECA, Gothenburg, Sweden)

11:30 IL12 - HTE Chemistry to Accelerate Medicinal Chemistry Programs

Dr Fabio LIMA (NOVARTIS, Basel, Switzerland)

Scientific Program

12:00 OC07 - New Precision Anti-TB Agents by Allosteric Inhibition of Glutamate-5-Kinase Enzyme

Prof. Concepcion GONZALEZ-BELLO (UNIVERSIDADE DE SANTIAGO DE COMPOSTELA - CIQUS, santiago de compostela, Spain)

12:15 OC08 - Impact of gem-Difluoromethylene Group on Physicochemical Properties in Medchem-Relevant Building Blocks

Dr Sergey RYABUKHIN (ENAMINE LTD, Kyiv, Ukraine)

12:30 Lunch & Exhibition

12:45 Company Workshop by Schrödinger: Augmenting Medicinal Chemistry with Digital Chemistry: A Lead Optimization Design Challenge for D-Amino Acid Oxidase Inhibitors

Mr Wade MILLER (SCHRÖDINGER, Cambridge, United States)

Session 6 - Enabling Chemistries for Chemical Biology Research

Session chair

Prof. Daniel HARKI (UNIVERSITY OF MINNESOTA, Minneapolis, MN, United States)

14:00 IL13 - Chemical Probes Enabling Drug Target Discovery and Validation

Prof. Edward TATE (IMPERIAL COLLEGE LONDON, London, United Kingdom)

14:30 IL14 - Generating Stem-Like T Cells with Small-Molecule Modulators for Cancer Immunotherapy

Prof. Peng WU

(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA, United States)

15:00 OC09 - Targeting Receptor Complexes with Therapeutic Peptides

Prof. Kristian STROMGAARD (UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

15:15 OC10 - Azetidin-2-Ones as Quenched Activity-Based Probes to Profile Human Neutrophil Elastase in Proteomes

Ms Rita FÉLIX

(IMED.ULISBOA - RESEARCH INSTITUTE FOR MEDICINES, Lisbon, Portugal)

15:30 Coffee break & Exhibition

16:00 PL03 -Carbohydrates in Health and Disease

Prof. Laura KIESSLING (MIT, Cambridge, MA, United States)

16:45 Poster session 2 (even numbers)

18:00 End of the scientific programme

20:00 Banquet (optional)

Scientific Program

Tuesday 13/06/2023

Session 7 - A Focus on Early Career Investigators

Session chair

Dr Melissa GRENIER-DAVIES (GLAXOSMITHKLINE, Cambridge, MA, United States)

09:00 IL15 - E3 Ligase Ligand Discovery for TPD

Dr Benika PINCH (NOVARTIS, Cambridge, MA, United States)

09:15 IL16 - Chemical Approaches to Enhance Cellular Immunotherapies

Dr Mark P. FARRELL (UNIVERSITY OF KANSAS, Lawrence, KS, United States)

09:30 IL17 - Machine Learning Tools to Accelerate Chemical Biology Studies

Dr Tiago RODRIGUES (UNIVERSITY OF LISBON, Lisbon, Portugal)

09:45 OC11 - Chemical Probes for RHO GEF/GTPase Complexes

Ms Mia CALLENS (UNIVERSITY OF OXFORD, Oxford, United Kingdom)

10:00 OC12 - Potent Targeted Activator of Cell Kill Molecules Selectively Eliminate HIV Infected Cells

Dr Abdellatif EL MARROUNI (MERCK & CO., West Point, United States)

10:15 OC13 - Borrowing Transcriptional Kinases to Activate Apoptosis Using Chemically Induced Proximity

Dr Roman SAROTT (STANFORD UNIVERSITY, Menlo Park, United States)

10:30 Coffee break & Exhibition

Session 8 - Approaches to Identify and Target Cryptic and Allosteric Pocket

Session chair

Dr Malin LEMURELL (ASTRAZENECA, Gothenburg, Sweden)

11:00 IL18 - A Computation-First Approach to Drug Challenging Disease Targets

Dr Woody SHERMAN (PSIVANT THERAPEUTICS, Boston, MA, United States)

11:30 IL19 - X-ray Crystallographic Fragment Screening for the Identification of Allosteric Binding Sites

Dr Andrew WOODHEAD (ASTEX THERAPEUTICS, Cambridge , United Kingdom)

12:00 IL20 - Exploiting Allostery for Computer-Aided Drug Design of Oncogenes

Dr Zoe COURNIA (BIOMEDICAL RESEARCH FOUNDATION ACADEMY OF ATHENS, Athens, Greece)

Scientific Program

12:30 OC14 - Structure-Based Drug Discovery and Umbrella Sampling Simulations Identify Novel Potent Troponin Calcium Sensitizers and Elucidate their Function

Prof. Steffen LINDERT (OSU, Columbus, United States)

12:45 Lunch & Exhibition

13:00 Company Workshop by CAS: The Evolution of Science at CAS: Connections Between Multi-disciplinary Data and Capabilities

Mrs Vee LINDSAY (CAS, Columbus, United States) Dr Angela ZHOU (CAS, Columbus, United States)

Session 9 - Getting Out of the Starting Block: New Hit Finding and Chemotype Advancement Methods

Session chair

Dr Carolyn DZIERBA (BRISTOL-MYERS SQUIBB, Cambridge, MA, United States)

14:00 IL21 - RAPID – a Next-Generation Chemoproteomics Technology Enabling the Discovery of Reversible Binders to Pre-specified Targets in Living Cells

Dr Justin RETTENMAIER (JNANA THERAPEUTICS, Boston, MA, United States)

14:30 IL22 - Covalent Fragment-Based Drug Discovery

Dr Daniel ERLANSON (FRONTIER MEDICINES, South San Francisco, CA, United States)

15:00 IL23 - Large-scale in Silico Fragment Screening of ~200 Million Fragments Based on Absolute Free Energy Perturbation

Dr Eric THERRIEN (SCHRODINGER, New York, NY, United States)

15:15 OC15 - Small Molecule Drug Discovery with Peptide-Encoded Libraries

Dr Nathalie GROB (MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, United States)

16:00 Closing Ceremony & Poster Prizes Ceremony

16:30 End of the Symposium

19:10 Boston Red Sox's game (optional)